Teijin collaborates with InCube Labs to boost health care business

Japan’s Teijin (TYO: 3401) says it has signed a strategic partnership agreement with InCube Labs, a California-based life science research lab, to accelerate Teijin’s health care business development. Financial terms of the deal were not disclosed.

As part of the accord, Teijin will invest in a company affiliated with InCube Labs. By leveraging its extensive network and expertise, InCube Labs will help Teijin to define strategic growth opportunities for its health care business. Initiatives will include competitive evaluation of Teijin technologies, analysis of key market characteristics and regulations, and provision of information to help Teijin identify promising business partners and M&A opportunities.

Health care is one of the growth drivers in the Teijin group's medium-to-long-term management vision. The group plans to integrate its materials and health care technologies to facilitate its expansion into fields including regenerative medicine and tissue repair, drug delivery systems and locomotive syndrome.